Kyle Gano Sells 1,541 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 1,541 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.87, for a total value of $235,572.67. Following the transaction, the chief executive officer now directly owns 136,778 shares in the company, valued at $20,909,252.86. This represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kyle Gano also recently made the following trade(s):

• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $151.20 on Thursday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The company has a market cap of $15.31 billion, a P/E ratio of 40.54 and a beta of 0.33. The firm has a 50-day simple moving average of $137.92 and a two-hundred day simple moving average of $131.51.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NBIX. Morgan Stanley lifted their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research note on Tuesday. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Wedbush reiterated an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Finally, UBS Group increased their price objective on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $166.85.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently bought and sold shares of the business. Golden State Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Brooklyn Investment Group grew its stake in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the period. Blue Trust Inc. increased its holdings in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares in the last quarter. R Squared Ltd acquired a new position in Neurocrine Biosciences during the fourth quarter worth $61,000. Finally, UMB Bank n.a. lifted its holdings in Neurocrine Biosciences by 211.6% during the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after purchasing an additional 309 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.